Health TrialsbyHealthPanel

Acute Skin Graft Versus Host Disease (GVHD)

1

Review clinical trials related to Acute Skin Graft Versus Host Disease (GVHD). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD) following allogenic hematopoietic stem cell transplantation (HSCT).

Participants needed: 10
Trial details
Phase: Phase 1Age: 2-35Biological sex: AllType: InterventionalSponsor: Children's Hospital Medical Center, CincinnatiUpdated: Sep 8, 2026Locations: 1
Eligibility criteria

Age ≥2 through age 35 years [+4]

Active uncontrolled skin infections. [+2]

Read more